SEP 02, 2015 01:30 PM PDT

Bioburden and Biofilm Control in the Pharmaceutical Industry

Presented At Microbiology
C.E. CREDITS: CE
Speakers
  • Manager, Sterility Assurance Research Center, Baxter Healthcare
    Biography
      Dr. Pasmore currently manages the Research Center in the Sterility Assurance department at Baxter Healthcare. His research includes biofilm analyses, rapid microbial methods, alternative sterilization techniques and new product development. He formerly has held the position of Assistant Research Professor at Montana State University, Department of Chemical Engineering. In his role at Montana State, he was the Medical Projects Supervisor at the Center for Biofilm Engineering where he studied biofilms in infection and medically systems, such as hemodialysis systems. Additionally, Dr. Pasmore worked as a Senior Engineer at STERIS Corporation where his research involved the evaluation and development of sterilization and decontamination technologies. He has multiple publications and presentations in the field of biofilm research and he is involved in several professional and standards organizations related to bacterial control and sterilization, including the PDA taskforce on BioburdenBiofilm Management.

    Abstract:

    The Pharmaceutical Industry has a diverse set of products all with varying level of microbial risk to patients. On the low risk extreme there are topical pharmaceuticals on the other extreme are the injectable solutions. The higher the risk of patient infection the more controls must be put in place to control microorganism during the manufacturing processes. Pharmaceutical manufacturing companies producing sterile injectables must be ever diligent to control bioburden (microorganism present in their manufacturing operations). One of the most challenging aspects of that bioburden, and one of the least understood, is that of biofilms. Biofilms create challenges related to harborage, detection, and remediation of the bioburden present in manufacturing operations. This talk will discuss some of the challenges that biofilms create for pharmaceutical manufacturing, as well as some of the current practices to remediate these issues.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...